Drugs / SP-8008
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04770194 | Oct 2019 → Jan 2020 | acute coronary syndrome, stroke disorder | Shin Poong Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-03-20 | Shin Poong Pharmaceutical Co. Ltd. | Regulatory 신풍제약 SP-8008 영국에서 임상 1상 승인 shinpoong.co.kr ↗
신풍제약 ( 대표 , 유제만 ) 은 19 일 항혈소판제 신약후보물질인 SP-8008 에 대한 비임상독성시험을 완료하고 , 영국의약품 ․ 보건의료제품규정청 (MHRA, Medicinesand Healthcare Products Regulatory Agency) 으로부터 임상 1 상시험승인 (CTA) 을 받았다 . |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-12-05 | Shin Poong Pharmaceutical Co. Ltd. | 새로운 작용기전의 항혈소판제 혁신신약 ‘SP-8008’ 영국에서 임상 1상 순항 중 shinpoong.co.kr ↗ |
| 2019-03-20 | Shin Poong Pharmaceutical Co. Ltd. | 신풍제약 SP-8008 영국에서 임상 1상 승인 shinpoong.co.kr ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SP-8008 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04770194 ↗ |
| Route | Oral | “Oral” NCT04770194 ↗ |